Actively Recruiting
UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)
Led by Cytopeutics Sdn. Bhd. · Updated on 2026-01-02
80
Participants Needed
1
Research Sites
158 weeks
Total Duration
On this page
Sponsors
C
Cytopeutics Sdn. Bhd.
Lead Sponsor
N
National University of Malaysia
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary objective of this study is to evaluate the functional recovery based on Barthel index (BI) and modified Rankin Scale (mRS) while the secondary objectives are to assess the survival and re-admission rate as well as to investigate the inflammatory response in a subclinical study within 1 year of Neuroncell-EX infusion in participants with acute ischemic stroke.
CONDITIONS
Official Title
UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must be aged 65 18 years old
- Patients with acute ischemic stroke symptom onset within 4 weeks
- Patients diagnosed with "moderate to severe" stroke based on NIHSS (6-24) at recruitment
- Patients who are not eligible for thrombolysis or thrombectomy
- Written informed consent by the patient or next-of-kin
You will not qualify if you...
- Patients who are medically unfit such as haemodynamically unstable or with deteriorating condition
- Patients with transient ischemic attack (TIA)
- Patients diagnosed with malignancy (past or present) or primary haematological disorders
- Patients with renal impairment with serum creatinine > 200 b5mol/l or creatinine clearance < 30 ml/min
- Patients with liver impairment with AST and ALT two times greater than upper normal limit
- Patients who are pregnant or breastfeeding
- Patients diagnosed with brain hemorrhage or other pathological brain disorders including vascular malformation, tumor, abscess, cardiogenic, inflammatory or infectious cerebral embolism, or severe brain atrophy
- Patients diagnosed or suspected with acute coronary syndrome
- Patients with congestive cardiac failure
- Patients with history of confirmed or suspected pulmonary embolism or chronic obstructive pulmonary disease (COPD)
- Patients with mental, cognitive or psychological disorders affecting understanding and adherence
- Patients undergoing experimental drug or instrument testing or participated in clinical drug trials in past 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Canselor Tuanku Muhriz UKM
Cheras, Kuala Lumpur, Malaysia, 56000
Actively Recruiting
Research Team
S
Sze Piaw Chin
CONTACT
N
Nik Syazana Saffery
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here